The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls
- PMID: 8255370
- DOI: 10.1007/BF00978370
The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls
Abstract
5- and 6-Hydroxydopamine, which we had earlier identified as naturally occurring amines in human urine, were quantified in Parkinson's patients treated with L-DOPA, Parkinson's patients whose treatment did not include L-DOPA and in age matched controls. Analysis was carried out by GC-MS of the ditrifluoromethylbenzoyl-trimethylsilyl (DTFMB-TMS) derivatives of the compounds. The concentrations of 5- and 6-hydroxydopamine in the urine of DOPA treated Parkinson's patients were significantly higher than the concentrations from patients not treated and from normal controls. Urinary dopamine levels were greatly elevated in DOPA treated Parkinson's patients while p-tyramine levels were suppressed. No marked differences were seen between the three groups in terms of the urinary concentrations of any of the other amines measured.
Similar articles
-
Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations.Clin Neurol Neurosurg. 1975;78(2):77-88. doi: 10.1016/s0303-8467(75)80014-x. Clin Neurol Neurosurg. 1975. PMID: 1222507
-
Effects of L-DOPA on the excretion of alcoholic metabolites of catecholamines and trace amines in rat and human urine.Biochem Med. 1981 Apr;25(2):135-48. doi: 10.1016/0006-2944(81)90070-3. Biochem Med. 1981. PMID: 6169341 No abstract available.
-
Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine.Ann Clin Biochem. 2014 Jan;51(Pt 1):38-46. doi: 10.1177/0004563213487894. Epub 2013 Jul 19. Ann Clin Biochem. 2014. PMID: 23873873
-
Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.Mov Disord. 2015 Jan;30(1):19-36. doi: 10.1002/mds.26120. Epub 2014 Dec 8. Mov Disord. 2015. PMID: 25488030 Review.
-
Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease.Ann N Y Acad Sci. 1992 May 11;648:71-86. doi: 10.1111/j.1749-6632.1992.tb24525.x. Ann N Y Acad Sci. 1992. PMID: 1637074 Review. No abstract available.
Cited by
-
EPC-K1, a hydroxyl radical scavenger, prevents 6-hydroxydopamine-induced dopamine depletion in the mouse striatum by up-regulation of catalase activity.Neurochem Res. 1999 Dec;24(12):1543-8. doi: 10.1023/a:1021152115752. Neurochem Res. 1999. PMID: 10591404
-
Neuroprotective Effect of Bergamot Juice in 6-OHDA-Induced SH-SY5Y Cell Death, an In Vitro Model of Parkinson's Disease.Pharmaceutics. 2020 Apr 5;12(4):326. doi: 10.3390/pharmaceutics12040326. Pharmaceutics. 2020. PMID: 32260543 Free PMC article.
-
Adult neurogenesis restores dopaminergic neuronal loss in the olfactory bulb.J Neurosci. 2014 Oct 22;34(43):14430-42. doi: 10.1523/JNEUROSCI.5366-13.2014. J Neurosci. 2014. PMID: 25339754 Free PMC article.
-
Adult Endogenous Dopaminergic Neuroregeneration Against Parkinson's Disease: Ideal Animal Models?Neurotox Res. 2021 Apr;39(2):504-532. doi: 10.1007/s12640-020-00298-7. Epub 2020 Nov 3. Neurotox Res. 2021. PMID: 33141428 Review.
-
Zingerone [4-(4-hydroxy-3-methoxyphenyl)-2-butanone] prevents 6-hydroxydopamine-induced dopamine depression in mouse striatum and increases superoxide scavenging activity in serum.Neurochem Res. 2005 Mar;30(3):325-32. doi: 10.1007/s11064-005-2606-3. Neurochem Res. 2005. PMID: 16018576
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous